NOV 28, 2019 8:25 AM PST

Immunotherapy Drug Shows Promise for Treating Advanced Prostate Cancer

WRITTEN BY: Annie Lennon

By the end of the year, an estimated 175,000 men in the United States will have been diagnosed with prostate cancer. Now, researchers from the UK have found a new way using immunotherapy to slow down the progression of the disease in its advanced stages, potentially adding an extra 2 years of lifespan to patients. 

The immunotherapy drug, known as pembrolizumab, works by blocking the activity of a molecule called PD-1, a protein that stops cells from identifying and tackling inflamed tissues and cancer cells. By blocking this protein, the drug allows the immune system to unleash T cells that are then able to combat both inflamed tissues and cancer cells. 

Already used to tackle other cancers such as melanoma, a new study by The Institute of Cancer Research, London, shows that it may be effective in treating advanced prostate cancer too. Conducted via a Phase II clinical trial, the drug was administered to 258 men with the disease who had become resistant to both androgen deprivation therapy and docetaxel chemotherapy. 

In total, the researchers found that 5% of the participants saw their tumours shrink or disappear, with 19% showing other evidence of tumor response. They also saw the average survival time following treatment among a group of 166 patients with very advanced stages of the disease and high levels of prostate-specific antigen (PSA) increase to 8.1 months. Meanwhile, a second group whose PSA levels were lower, even though the disease had spread to the bone, lived for an average of 14.1 months after treatment. 

In particular, the researchers found the most dramatic responses in patients whose tumors had mutations in genes that repair DNA. Known as “super-responders”, Johann de Bono, Regius Professor of cancer research at The Institute of Cancer Research, London, said, “Our study has shown that a small proportion of men with very advanced prostate cancer are super responders to immunotherapy and could live for at least two years and possibly considerably longer.”

Professor Paul Workman, chief executive of The Institute of Cancer Research, London, added, “Immunotherapy has had tremendous benefits for some cancer patients and it's fantastic news that even in prostate cancer, where we don't see much immune activity, the proportion of men are responding well to treatment….'It's encouraging to see testing for DNA repair mutations may identify some patients who are more likely to respond, and I'm keen to see how the new, larger trial in this group of patients plays out.”


Sources: Melanoma Research Alliance, Daily Mail and BBC News

About the Author
  • Science writer with keen interests in technology and behavioral biology. Her current focus is on the interplay between these fields to create meaningful interactions, applications and environments.
You May Also Like
JAN 01, 2021
Microbiology
A New Type of Antibiotics Help the Immune System Fight Pathogens
JAN 01, 2021
A New Type of Antibiotics Help the Immune System Fight Pathogens
Reporting in Nature, scientists have identified a new group of compounds that may help us get out of the antibiotic-resi ...
JAN 05, 2021
Drug Discovery & Development
Promising Epigenetic Treatment for Depression Works After One Dose
JAN 05, 2021
Promising Epigenetic Treatment for Depression Works After One Dose
Researchers affiliated with the University of Sao Paulo in Brazil have used epigenetic modulators to reduce stress-induc ...
JAN 13, 2021
Immunology
Antibodies Gain the Upper Hand Against Sly Tumors
JAN 13, 2021
Antibodies Gain the Upper Hand Against Sly Tumors
Tumors use ingenious approaches to stay just out of reach of immune cells on patrol and avoid detection. Indeed, cancer ...
JAN 18, 2021
Immunology
Arthritis Drug Approved for Critically Ill COVID Patients
JAN 18, 2021
Arthritis Drug Approved for Critically Ill COVID Patients
Critically ill COVID patients in the U.K. may receive an arthritis drug after a study showed that treatment lowered mort ...
FEB 18, 2021
Cell & Molecular Biology
Inhibition of a Specific Enzyme Could be a Way to Treat Glioblastoma
FEB 18, 2021
Inhibition of a Specific Enzyme Could be a Way to Treat Glioblastoma
Researchers may have identified a new treatment target for a deadly form of brain cancer. Inhibiting an enzyme called PR ...
MAR 04, 2021
Infographics
All You Need to Know about COVID-19 Vaccines
MAR 04, 2021
All You Need to Know about COVID-19 Vaccines
After over a year lockdowns brought on by the pandemic, hopes for returning to something even similar to ' ...
Loading Comments...